Long noncoding RNA SNHG6 mainly functions as a competing endogenous RNA in human tumors

Wang, Huishan; Zhang, Wen; Zhu, Hongyi; Li, Quanpeng; Ma, Lin

doi:10.1186/s12935-020-01303-x

Cited by 21 publications

(16 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have shown that lncRNAs often sponge many different types of miRNAs, acting as competing endogenous RNAs (ceRNAs) to achieve their function 22 - 24 . Because Linc01612 is mainly located in the cytoplasm, it is suspected that Linc01612 may function as a ceRNA to recover ATF3 expression by sponging miRNAs in HCC progression.…”

Section: Resultsmentioning

confidence: 99%

Long noncoding RNA Linc01612 represses hepatocellular carcinoma progression by regulating miR-494/ATF3/p53 axis and promoting ubiquitination of YBX1

Liu¹,

Song²,

Guo³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) play an important role in the progression of hepatocellular carcinoma (HCC). Linc01612 is a novel lncRNA that function remains unknown in the progression of cancers, including HCC. In this study, we discovered that Linc01612 is significantly down-regulated in HCC tissues than in non-tumor tissues and correlated with poor prognosis. Linc01612 mainly localizes in the cytoplasm and functions as a tumor suppressor by repressing the growth and metastasis of hepatoma cells in vitro and in vivo . Mechanistically, in p53-expressing hepatoma cells, Linc01612 acts as a competitive endogenous RNA and promotes the expression of activation transcription factor 3 (ATF3) by sponging microRNA-494 (miR-494), which in turn inhibits MDM2-mediated ubiquitination of p53 and activates the p53 pathway. Furthermore, in p53-null hepatoma cells, Linc01612 exerts its biological functions by physically interacting with Y-box binding protein 1 protein (YBX1) and promoting the ubiquitin-mediated degradation of YBX1. Interestingly, the Linc01612-YBX1 signaling pathway is also present in p53-expressing hepatoma cells. In conclusion, our study indicated that Linc01612 is a functional lncRNA in HCC and Linc01612 may serve as a potential diagnostic biomarker and therapeutic target for HCC.

show abstract

Section: Resultsmentioning

confidence: 99%

Long noncoding RNA Linc01612 represses hepatocellular carcinoma progression by regulating miR-494/ATF3/p53 axis and promoting ubiquitination of YBX1

Liu¹,

Song²,

Guo³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…To allow stratification of each patient according to their genomic characteristics, we successfully constructed a prognostic model using five FRLs, including SNHG6, LINC02298, AP000851.2, RPARP-AS1, and AL162274.1. Numerous studies have confirmed the prognostic value and clinical potential of SNHG6 in cancer, serving as a competitive endogenous RNA as one of the primary mechanisms underlying its role ( 84 ). According to Xu et al., SNHG6 expression is abnormally upregulated and regulated by SP1 in colorectal cancer, not only that SNHG6 promotes epithelial-mesenchymal transition and accelerates colorectal cancer growth and metastasis by competitively bound to miR-26a/b and miR-214 ( 85 ).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of a Ferroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Landscape in Osteosarcoma

Zhang

Liu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Research on the implications of ferroptosis in tumors has increased rapidly in the last decades. There are evidences that ferroptosis is involved in several aspects of cancer biology, including tumor progression, metastasis, immunomodulation, and therapeutic response. Nonetheless, the interaction between ferroptosis-related lncRNAs (FRLs) and the osteosarcoma immune microenvironment is poorly understood. In this study, a risk model composed of FRLs was developed using univariate and LASSO Cox regression analyses. On the basis of this model, FRL scores were calculated to systematically explore the role of the model in predicting the prognosis and immune characteristics of osteosarcoma patients. Survival analysis showed that osteosarcoma samples with lower FRL-score had better overall survival. After predicting the abundance of immune cells in osteosarcoma microenvironment by single-sample gene-set enrichment analysis (ssGSEA) and ESTIMATE analysis, we found that the FRL-score could distinguish immune function, immune score, stromal score, tumor purity, and tumor infiltration of immune cells in different osteosarcoma patients. In addition, FRL-score was also associated with immune checkpoint gene expression and half-maximal inhibitory concentration of chemotherapeutic agents. Finally, we confirmed that knockdown of RPARP-AS1 suppressed the malignant activity of osteosarcoma cells in vitro experiments. In general, the FRL-based prognostic signature could promote our understanding of the immune microenvironment characteristics of osteosarcoma and guide more effective treatment regimens.

show abstract

“…Knockdown of SNHG6 also inhibited BC cell migration, invasion and the EMT process. Besides BC, SNHG6 has been implicated as an important player in various tumors, such as hepatocellular carcinoma, gastric cancer, and bladder cancer [26][27][28]. Elevated SNHG6 level has been reported in those cancer cells and this elevation accelerates cancer cell proliferation and migration, indicating that SNHG6 has a conserved role as an oncogenic factor.…”

Section: Discussionmentioning

confidence: 99%

LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis

Wang

Huang

Chen

et al. 2021

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Breast cancer (BC) is the most prevalent cancer in women with an estimated incidence of 10% and the leading cause of mortality due to its heterogenous property and high metastasis rate. Development of novel therapy is very necessary and requires an understanding of molecular mechanisms. We investigated the function of SNHG6/miR-543/LAMC1 axis in BC. Methods Human BC tissues were obtained from diagnosed patients. BC cell lines and normal breast cells were used. QRT-PCR and Western blotting were employed to measure expression levels of SNHG6, miR-543, LAMC1, EMT-related proteins, and PI3K/AKT pathway. Dual-luciferase assay was performed to validate interactions of SNHG6/miR-543 and miR-543/ LAMC1. Colony formation assay, flow cytometry, scratch wound healing assay, and transwell assay were utilized to assess the proliferation, apoptosis, migration, and invasion of BC cells. Nude mouse xenograft model was used the evaluate the function of SNHG6/miR-543 in tumor growth in vivo. Results SNHG6 and LAMC1 were elevated, but miR-543 was reduced in BC tissues and cells. SNHG6 interacted directly with miR-543, while miR-543 targeted LAMC1. Knockdown of SNHG6 suppressed BC cell proliferation, migration, invasion, EMT, and PI3K/AKT pathway, but promoted cell apoptosis, while miR-543 inhibitor or overexpression of LAMC1 reversed those effects. Overexpression of LAMC1 also blocked the effects of miR-543 on BC cell proliferation, migration, invasion, and EMT. Knockdown of SNHG6 restrained BC growth in vivo, while miR-543 inhibitor inhibited that suppression. Conclusion SNHG6 promoted EMT and BC cell proliferation and migration by acting as a miR-543 sponge and disinhibiting LAMC1/PI3K/AKT pathway. SNHG6/miR-543/LAMC1 axis could serve as candidates for the development of therapeutic strategies for BC.

show abstract

Long noncoding RNA SNHG6 mainly functions as a competing endogenous RNA in human tumors

Cited by 21 publications

References 49 publications

Long noncoding RNA Linc01612 represses hepatocellular carcinoma progression by regulating miR-494/ATF3/p53 axis and promoting ubiquitination of YBX1

Long noncoding RNA Linc01612 represses hepatocellular carcinoma progression by regulating miR-494/ATF3/p53 axis and promoting ubiquitination of YBX1

Comprehensive Analysis of a Ferroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Landscape in Osteosarcoma

LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis

Contact Info

Product

Resources

About